Vivo Capital
Vivo Capital reported 50 stocks worth $909M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PRAX (8.7%), TRVI (6.7%) and ERAS (6.5%). Compared with Q2 2026, the fund opened new positions in ENTX, KRSA and BLSM, added to AVBP, ANRO and FTH, trimmed TRVI, ERAS and SABS and sold out of SVA, DNTH and GERN.
Latest filing: what Vivo Capital did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PRAX Praxis Precision Medicines I | $79M | 8.7% | 271K | No change | 6 of 8 | |
| 2 | ![]() TRVI Trevi Therapeutics Inc | $60.6M | 6.7% | 4.2M | −865K (−17%) | 8 of 8 | |
| 3 | ![]() ERAS Erasca Inc | $58.9M | 6.5% | 4M | −107K (−3%) | 8 of 8 | |
| 4 | ![]() AVBP Arrivent Biopharma Inc | $54.1M | 6.0% | 1.8M | +105K (+6%) | 3 of 8 | |
| 5 | ![]() ABVX Abivax SA | $41.1M | 4.5% | 415K | No change | 5 of 8 | |
| 6 | ![]() ENTX Entera Bio Ltd | $35.7M | 3.9% | 12.3M | New position | 1 of 8 | |
| 7 | ![]() ACRS Aclaris Therapeutics Inc | $35.2M | 3.9% | 6.7M | No change | 8 of 8 | |
| 8 | ![]() ANRO Alto Neuroscience Inc | $34.7M | 3.8% | 1.4M | +151K (+12%) | 4 of 8 | |
| 9 | ![]() TNGX Tango Therapeutics Inc | $34.4M | 3.8% | 1.4M | No change | 6 of 8 | |
| 10 | ![]() CRVS Corvus Pharmaceuticals Inc | $32.3M | 3.6% | 2.8M | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Vivo Capital 13F FAQ
What does Vivo Capital own?
Vivo Capital reported 50 stocks worth $909M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are PRAX (8.7%), TRVI (6.7%) and ERAS (6.5%). The table above lists every position in the filing (the top 10 without an account).
What did Vivo Capital buy and sell in Q3 2026?
Compared with Q2 2026: 8 new positions, 5 added to, 8 trimmed and 5 sold out. New positions include ENTX, KRSA and BLSM. It sold all of SVA, DNTH and GERN.
When will Vivo Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Vivo Capital's portfolio worth?
The Q3 2026 filing reports $909M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

























